Provided by Tiger Trade Technology Pte. Ltd.

Merck

142.38
-0.4100-0.29%
Post-market: 142.450.0723+0.05%19:10 EDT
Volume:8.41M
Turnover:1.19B
Market Cap:351.28B
PE:111.86
High:142.77
Open:141.90
Low:138.89
Close:142.79
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.01
T/O Rate:0.34%
Dividend:3.32
Dividend Rate:2.33%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.38
PE(LYR):19.56

Loading ...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

Merck Price Target Raised to $161.00/Share from $127.00 by Leerink Partners

Dow Jones
·
Sep 10

Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127

THOMSON REUTERS
·
Sep 09

Merck price target raised to $161 from $127 at Leerink

TIPRANKS
·
Sep 09

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 09

Merck CEO Davis, R&D Head Li to Speak at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 08

Guggenheim Adjusts Price Target on Merck & Co. to $170 From $146, Maintains Buy Rating

MT Newswires Live
·
Sep 08

Merck & Co Inc : Guggenheim Raises Target Price to $170 from $146

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Merck & Company (MRK)

TIPRANKS
·
Sep 08

Merck KGaA (0O14) Gets a Hold from Barclays

TIPRANKS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 08

Merck & Co. Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Merck Price Target Raised to $170.00/Share from $150.00 by Wells Fargo

Dow Jones
·
Sep 04

Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...

Dow Jones
·
Sep 04

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

Jefferies Reaffirms Their Hold Rating on Merck KGaA (0O14)

TIPRANKS
·
Sep 03